TG Therapeutics (NASDAQ:TGTX) Sets New 1-Year High - What's Next?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report)'s share price reached a new 52-week high on Thursday . The stock traded as high as $27.79 and last traded at $27.42, with a volume of 254056 shares traded. The stock had previously closed at $27.17.

Analysts Set New Price Targets

TGTX has been the topic of several research analyst reports. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday. HC Wainwright raised their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday. TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, B. Riley lifted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $37.67.

TG Therapeutics Stock Performance

The stock's 50-day moving average price is $23.65 and its 200 day moving average price is $20.30. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.65% and a negative net margin of 5.42%. The business had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. The company's revenue for the quarter was down 49.4% on a year-over-year basis. Analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Quest Partners LLC bought a new position in TG Therapeutics in the 3rd quarter valued at $246,000. Thrivent Financial for Lutherans bought a new position in shares of TG Therapeutics in the third quarter valued at about $2,450,000. Mutual of America Capital Management LLC acquired a new position in TG Therapeutics during the 3rd quarter worth about $469,000. Empowered Funds LLC grew its holdings in TG Therapeutics by 3.1% during the 3rd quarter. Empowered Funds LLC now owns 46,431 shares of the biopharmaceutical company's stock worth $1,086,000 after acquiring an additional 1,386 shares during the last quarter. Finally, KBC Group NV raised its stake in shares of TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock worth $109,000 after acquiring an additional 1,092 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.